Skye Bioscience, Inc. Quarterly report pursuant to Section 13 or 15(d)

Warrants and Derivative Liabilities (Details 1)

Warrants and Derivative Liabilities (Details 1) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended
	Feb. 28, 2018	Jan. 31, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Fair Value Of Derivative Liabilities [Roll Forward]
Fair Value of Derivative Liabilities		$ 558,037			$ 558,037	$ 1,231,129
Fair Value of Derivative Liabilities Issued	$ 5,707,423	4,717,211			10,424,634
Change in fair value of warrant liabilities			$ 1,580,242	$ (26,437)	417,749	(38,998)
Reclassification of Derivatives to Equity					(1,308,581)	(5,238)
Fair Value of Derivative Liabilities			10,091,839	1,098,361	10,091,839	1,098,361
Emerald Financing - Warrant Liability
Fair Value Of Derivative Liabilities [Roll Forward]
Fair Value of Derivative Liabilities		0			0
Fair Value of Derivative Liabilities Issued					10,424,634
Change in fair value of warrant liabilities					(814,071)
Reclassification of Derivatives to Equity					0
Fair Value of Derivative Liabilities			9,610,563		9,610,563
Series B Preferred Stock Conversion Liability
Fair Value Of Derivative Liabilities [Roll Forward]
Fair Value of Derivative Liabilities		6,715			6,715	118,821
Fair Value of Derivative Liabilities Issued					0	0
Change in fair value of warrant liabilities					0	(88,532)
Reclassification of Derivatives to Equity					(6,715)	(5,238)
Fair Value of Derivative Liabilities			0	25,051	0	25,051
Series B Warrant Liability
Fair Value Of Derivative Liabilities [Roll Forward]
Fair Value of Derivative Liabilities		$ 551,322			551,322	1,112,308
Fair Value of Derivative Liabilities Issued					0	0
Change in fair value of warrant liabilities					1,231,820	(38,998)
Reclassification of Derivatives to Equity					(1,301,866)	0
Fair Value of Derivative Liabilities			$ 481,276	$ 1,073,310	$ 481,276	$ 1,073,310